Show simple item record

dc.contributor.authorBroadley, Simon A
dc.contributor.authorBarnett, Michael H
dc.contributor.authorBoggild, Mike
dc.contributor.authorBrew, Bruce J
dc.contributor.authorButzkueven, Helmut
dc.contributor.authorHeard, Robert
dc.contributor.authorHodgkinson, Suzanne
dc.contributor.authorKermode, Allan G
dc.contributor.authorLechner-Scott, Jeannette
dc.contributor.authorMacdonell, Richard AL
dc.contributor.authorMarriott, Mark
dc.contributor.authorMason, Deborah F
dc.contributor.authorParratt, John
dc.contributor.authorReddel, Stephen W
dc.contributor.authorShaw, Cameron P
dc.contributor.authorSlee, Mark
dc.contributor.authorSpies, Judith
dc.contributor.authorTaylor, Bruce V
dc.contributor.authorCarroll, William M
dc.contributor.authorKilpatrick, Trevor J
dc.contributor.authorKing, John
dc.contributor.authorMcCombe, Pamela A
dc.contributor.authorPollard, John D
dc.contributor.authorWilloughby, Ernest
dc.date.accessioned2018-09-05T01:30:37Z
dc.date.available2018-09-05T01:30:37Z
dc.date.issued2014
dc.identifier.issn0967-5868
dc.identifier.doi10.1016/j.jocn.2014.01.017
dc.identifier.urihttp://hdl.handle.net/10072/68922
dc.description.abstractIn this third and final part of our review of multiple sclerosis (MS) treatment we look at the practical day-to-day management issues that are likely to influence individual treatment decisions. Whilst efficacy is clearly of considerable importance, tolerability and the potential for adverse effects often play a significant role in informing individual patient decisions. Here we review the issues surrounding switching between therapies, and the evidence to assist guiding the choice of therapy to change to and when to change. We review the current level of evidence with regards to the management of women in their child-bearing years with regards to recommendations about treatment during pregnancy and whilst breast feeding. We provide a summary of recommended pre- and post-treatment monitoring for the available therapies and review the evidence with regards to the value of testing for antibodies which are known to be neutralising for some therapies. We review the occurrence of adverse events, both the more common and troublesome effects and those that are less common but have potentially much more serious outcomes. Ways of mitigating these risks and managing the more troublesome adverse effects are also reviewed. Finally, we make specific recommendations with regards to the treatment of MS. It is an exciting time in the world of MS neurology and the prospects for further advances in coming years are high.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherChurchill Livingstone
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom1857
dc.relation.ispartofpageto1865
dc.relation.ispartofissue11
dc.relation.ispartofjournalJournal of Clinical Neuroscience
dc.relation.ispartofvolume21
dc.rights.retentionY
dc.subject.fieldofresearchMedical and Health Sciences not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchcode119999
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1109
dc.titleTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.hasfulltextNo Full Text
gro.griffith.authorBroadley, Simon
gro.griffith.authorButzkueven, Helmut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record